Jazz Pharmaceuticals traded at $145.47 this Wednesday May 25th, increasing $2.49 or 1.74 percent since the previous trading session. Looking back, over the last four weeks, Jazz Pharmaceuticals gained 12.44 percent. Over the last 12 months, its price fell by 18.14 percent. Looking ahead, we forecast Jazz Pharmaceuticals to be priced at 144.47 by the end of this quarter and at 128.90 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
145.47
Daily Change
1.74%
Yearly
-18.14%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 151.98 2.86 1.92% 32.50%
Aerie Pharmaceuticals 5.62 -0.31 -5.23% -66.43%
ALKERMES 28.70 0.35 1.23% 32.93%
Amarin 1.36 0.05 3.82% -70.37%
Antares Pharma 5.59 0 0% 37.01%
Cara Therapeutics 8.13 -0.15 -1.75% -40.26%
Coherus Biosciences 7.71 0.04 0.52% -41.32%
Emergent BioSolutions 34.43 1.10 3.30% -39.18%
Endo International 0.40 0.04 9.70% -92.83%
Halozyme Therapeutics 45.09 0.27 0.60% 6.77%
Hikma Pharmaceutical 1,675.00 -15.00 -0.89% -32.81%
Heron Therapeutics 3.19 0.03 0.79% -77.25%
Horizon Pharma 88.43 0.40 0.45% -5.62%
Ionis Pharmaceuticals 37.19 0.08 0.22% 5.41%
Lannett 0.51 0 0% -89.46%
Eli Lilly 307.02 1.06 0.35% 52.75%
McKesson 333.33 4.53 1.38% 71.55%
Merck & Co 93.74 -0.91 -0.96% 21.37%
Nektar Therapeutics 3.39 0 0% -80.71%
Phibro Animal Health 18.28 -0.22 -1.19% -33.70%
Pacira 60.99 0.34 0.55% -8.16%
Pfizer 53.72 0.31 0.58% 38.03%
Perrigo 39.21 0.69 1.79% -16.09%
Revance Therapeutics 12.59 -0.21 -1.64% -55.18%
Supernus Pharmaceuticals 27.11 0.13 0.48% -9.36%
Teva Pharmaceutical Industries 8.53 0.08 0.95% -18.61%
Xeris Pharmaceuticals Inc 1.98 0.02 0.89% -40.08%
Zoetis 163.18 0.13 0.08% -7.61%


Jazz Pharmaceuticals
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.